Why the study?
Does elimination of cyclosporine A improve health-related quality-of-life in kidney transplant patients on sirolimus-based therapy?
Population
430 kidney transplant patients after 3 months of combined sirolimus, cyclosporine A, and steroids treatment
Comparison
Sirolimus plus steroids vs Sirolimus, cyclosporine A, and steroids
Design
RCT, randomly assigned, open-label
Follow-up
2 years
Authors
Loading...
Supports early cyclosporine elimination in sirolimus regimens for kidney transplant QoL gains; extends RCT evidence to fatigue and vitality domains.
Does elimination of cyclosporine A improve health-related quality-of-life in kidney transplant patients on sirolimus-based therapy?
Early elimination of cyclosporine A from a sirolimus-based regimen improves fatigue, vitality, and appearance-related quality of life in kidney transplant recipients.
Oberbauer et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: